Try our beta test site
1 study found for:    18486740 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
Condition: Psoriasis
Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg;   Drug: Ustekinumab (CNTO 1275) 45 mg;   Drug: Ustekinumab (CNTO 1275) 90 mg

Study has passed its completion date and status has not been verified in more than two years.